Immunotherapy: 1999-2004

Research output: Contribution to journalArticle

Abstract

Allergen immunotherapy continues to be used worldwide in the management of allergic rhinitis and asthma. We continue to refine our knowledge of the indications for immunotherapy, the allergens that can be used successfully, and the requirements for dosage and route of administration. Several additional allergens have been shown to be effective in controlled studies. The sublingual route of administration is safe and can be effective if the dose is large enough. Since reviews in 1998, further studies of immunologic changes after immunotherapy have confirmed that TH2 lymphocyte-mediated responses are suppressed, and TH1 responses are stimulated. Eosinophil and basophil inflammatory responses to allergen exposure are downregulated through one or both of these mechanisms. Research continues to seek improvements through allergen vaccine modifications suggested by recent immunologic discoveries. None of these is available in practice.

Original languageEnglish (US)
Pages (from-to)1013-1023
Number of pages11
JournalThe Journal of Allergy and Clinical Immunology
Volume113
Issue number6
DOIs
StatePublished - Jun 2004

Fingerprint

Immunotherapy
Allergens
Immunologic Desensitization
Sublingual Administration
Basophils
Eosinophils
Down-Regulation
Vaccines
Asthma
Lymphocytes
Research
Allergic Rhinitis

Keywords

  • allergen
  • anti-IgE
  • basophil
  • CpG motif
  • cytokines
  • Immunotherapy
  • LAR
  • Late asthmatic reaction
  • mast cell
  • peptide
  • RI
  • Rush immunotherapy
  • Signaling lymphocytic activation molecule
  • SLAM
  • SLIT
  • Sublingual immunotherapy
  • T cells
  • T-cell receptor
  • TCR

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Immunotherapy : 1999-2004. / Norman, Philip S.

In: The Journal of Allergy and Clinical Immunology, Vol. 113, No. 6, 06.2004, p. 1013-1023.

Research output: Contribution to journalArticle

@article{d4db76e4bc0d4100a85368d39fe12ff3,
title = "Immunotherapy: 1999-2004",
abstract = "Allergen immunotherapy continues to be used worldwide in the management of allergic rhinitis and asthma. We continue to refine our knowledge of the indications for immunotherapy, the allergens that can be used successfully, and the requirements for dosage and route of administration. Several additional allergens have been shown to be effective in controlled studies. The sublingual route of administration is safe and can be effective if the dose is large enough. Since reviews in 1998, further studies of immunologic changes after immunotherapy have confirmed that TH2 lymphocyte-mediated responses are suppressed, and TH1 responses are stimulated. Eosinophil and basophil inflammatory responses to allergen exposure are downregulated through one or both of these mechanisms. Research continues to seek improvements through allergen vaccine modifications suggested by recent immunologic discoveries. None of these is available in practice.",
keywords = "allergen, anti-IgE, basophil, CpG motif, cytokines, Immunotherapy, LAR, Late asthmatic reaction, mast cell, peptide, RI, Rush immunotherapy, Signaling lymphocytic activation molecule, SLAM, SLIT, Sublingual immunotherapy, T cells, T-cell receptor, TCR",
author = "Norman, {Philip S.}",
year = "2004",
month = "6",
doi = "10.1016/j.jaci.2004.03.020",
language = "English (US)",
volume = "113",
pages = "1013--1023",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - Immunotherapy

T2 - 1999-2004

AU - Norman, Philip S.

PY - 2004/6

Y1 - 2004/6

N2 - Allergen immunotherapy continues to be used worldwide in the management of allergic rhinitis and asthma. We continue to refine our knowledge of the indications for immunotherapy, the allergens that can be used successfully, and the requirements for dosage and route of administration. Several additional allergens have been shown to be effective in controlled studies. The sublingual route of administration is safe and can be effective if the dose is large enough. Since reviews in 1998, further studies of immunologic changes after immunotherapy have confirmed that TH2 lymphocyte-mediated responses are suppressed, and TH1 responses are stimulated. Eosinophil and basophil inflammatory responses to allergen exposure are downregulated through one or both of these mechanisms. Research continues to seek improvements through allergen vaccine modifications suggested by recent immunologic discoveries. None of these is available in practice.

AB - Allergen immunotherapy continues to be used worldwide in the management of allergic rhinitis and asthma. We continue to refine our knowledge of the indications for immunotherapy, the allergens that can be used successfully, and the requirements for dosage and route of administration. Several additional allergens have been shown to be effective in controlled studies. The sublingual route of administration is safe and can be effective if the dose is large enough. Since reviews in 1998, further studies of immunologic changes after immunotherapy have confirmed that TH2 lymphocyte-mediated responses are suppressed, and TH1 responses are stimulated. Eosinophil and basophil inflammatory responses to allergen exposure are downregulated through one or both of these mechanisms. Research continues to seek improvements through allergen vaccine modifications suggested by recent immunologic discoveries. None of these is available in practice.

KW - allergen

KW - anti-IgE

KW - basophil

KW - CpG motif

KW - cytokines

KW - Immunotherapy

KW - LAR

KW - Late asthmatic reaction

KW - mast cell

KW - peptide

KW - RI

KW - Rush immunotherapy

KW - Signaling lymphocytic activation molecule

KW - SLAM

KW - SLIT

KW - Sublingual immunotherapy

KW - T cells

KW - T-cell receptor

KW - TCR

UR - http://www.scopus.com/inward/record.url?scp=3042840183&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042840183&partnerID=8YFLogxK

U2 - 10.1016/j.jaci.2004.03.020

DO - 10.1016/j.jaci.2004.03.020

M3 - Article

C2 - 15208577

AN - SCOPUS:3042840183

VL - 113

SP - 1013

EP - 1023

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 6

ER -